Author Title Type [ Year(Asc)]
Filters: Author is Nakamura, Ryotaro  [Clear All Filters]
Murthy GSubramania, Kim S, Estrada-Merly N, Abid MBilal, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, et al. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023.
Ngo D, Chen J, Tinajero J, Aribi A, Arslan S, Marcucci G, Nakamura R, Malki MMAl, Forman SJ, Dadwal S, et al. The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study. Stem Cell Res Ther. 2023;14(1):95.
Epstein JB, Hernandez RS, Nakamura R, Yost SE, Ali H. Oral Chronic Graft-versus-Host Disease in Post-Hematopoietic Stem Cell Transplant Patients Following SARS-CoV-2 Vaccination: Case Reports. Case Rep Oncol. 2023;16(1):1287-1292.
Agrawal V, Pourhassan H, Tsai N-C, Ngo D, Koller P, Malki MMAl, Salhotra A, Ali H, Aribi A, Sandhu KS, et al. Post-transplant sinusoidal obstruction syndrome in adult patients with B-cell Acute Lymphoblastic Leukemia treated with pre-transplant Inotuzumab. Transplant Cell Ther. 2023.
Mei M, Palmer J, Tsai NNi-Chun, Simpson J, O'Hearn J, Stein A, Forman S, Spielberger R, Cai J-L, Htut M, et al. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma. Clin Lymphoma Myeloma Leuk. 2023.
Tamari R, McLornan DP, Ahn KWoo, Estrada-Merly N, Hernández-Boluda JCarlos, Giralt SA, Palmer JM, Gale RPeter, DeFilipp Z, Marks D, et al. A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood Adv. 2023.
Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, et al. Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Transplant Cell Ther. 2023.
Nusrat S, Davis H, MacDougall K, George JN, Nakamura R, Borogovac A. Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians. J Intensive Care Med. 2023:8850666231200193.
Feurstein SK, Trottier AM, Estrada-Merly N, Pozsgai MJ, McNeely KE, Drazer MW, Ruhle B, Sadera K, Koppayi AL, Scott BL, et al. Germline predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood. 2022.
DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, et al. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines. Transplant Cell Ther. 2022.
Khaled SK, Claes K, Goh YTee, Kwong YLam, Leung N, Mendrek W, Nakamura R, Sathar J, Ng E, Nangia N, et al. Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. J Clin Oncol. 2022:JCO2102389.
Murthy HS, Ahn KWoo, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2022.
Pourhassan H, La Rosa C, Chiuppesi F, Puing A, Aldoss I, Park Y, Zhou Q, Karpinski V, Faircloth K, Kaltcheva T, et al. Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity. Blood Adv. 2022.